Product Images Lansoprazole

This is a graph with three lines representing the average severity of heartburn experienced by patients, measured on a scale of 0 (none) to 3 (severe), over time (in days) for three different groups: a placebo group, a group taking 15 mg of lansoprazole once a day, and a group taking 30 mg of lansoprazole once a day. The x-axis represents the days from the start of treatment and the y-axis represents the severity of heartburn.*

The text provides a graph showing the mean severity of night heartburn by study day for evaluable patients. The severity is measured on a scale of 0 to 3, with 0 representing no heartburn and 3 representing severe heartburn. Three treatment groups are shown: placebo, lansoprazole 16 mg QD, and lansoprazole 30 mg QD. The x-axis shows the days from the start of treatment.*

This is a medication guide for Lansoprazole Delayed-Release Orally Disintegrating Tablets manufactured by Aurobindo. It contains instructions for use and administration. The tablets should not be chewed and can be swallowed with or without water. An alternative method of administration is through ralsyinge for children or patients with difficulty swallowing. The medication guide also includes information on storage and child-resistant packaging. The tablets contain 30 g of Lansoprazole USP and are not suitable for people with phenylketonuria. Printed medication guides can be found on the Aurobindo website.*